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Abstract
Objective—To explore darunavir/ritonavir (DRV/r) plus raltegravir (RAL) combination therapy
in antiretroviral-naive patients.
Design—Phase IIb, single-arm, open-label, multicenter study.
Methods—One hundred and twelve antiretroviral-naive, HIV-1-infected patients received DRV/r
800/100 mg once daily and RAL 400 mg twice daily. Primary endpoint was virologic failure by
week 24. Virologic failure was defined as confirmed viral load of 1000 copies/ml or more at week
12, or an increase of more than 0.5 log10 copies/ml in viral load from week 4 to 12, or a confirmed
viral load of more than 50 copies/ml at or after week 24. Protease and integrase genes were
sequenced in patients experiencing virologic failure.
Results—Virologic failure rate was 16% [95% confidence interval (CI) 10–24] by week 24 and
26% (95% CI 19–36) by week 48 in an intent-to-treat analysis. Viral load at virologic failure was
51–200 copies/ml in 17/28 failures. Adjusting for age and sex, virologic failure was associated
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with baseline viral load of more than 100 000 copies/ml [hazard ratio 3.76, 95% CI (1.52–9.31), P
=0.004] and lower CD4 cell count [0.77 per 100 cells/μl increase (95% CI 0.61–0.98), P =0.037].
When trough RAL concentrations were included as a time-varying covariate in the analysis,
virologic failure remained associated with baseline viral load more than 100 000 copies/ml [hazard
ratio =4.67 (95% CI 1.93–11.25), P <0.001], whereas RAL level below detection limit in plasma
at one or more previous visits was associated with increased hazard [hazard ratio =3.42 (95% CI
1.41–8.26), P =0.006]. All five participants with integrase mutations during virologic failure had
baseline viral load more than 100 000 copies/ml.
Conclusion—DRV/r plus RAL was effective and well tolerated in most patients, but virologic
failure and integrase resistance were common, particularly in patients with baseline viral load
more than 100 000 copies/ml.
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Introduction
Reverse transcriptase inhibitor (RTI) sparing antiretroviral regimens are needed given
potential toxicities of some nucleos(t)ide RTIs (NRTIs) [1] and the frequency of transmitted
NRTI and nonnucleoside RTI (NNRTI) resistance [2]. Two fully active antiretroviral drugs
may be sufficient to suppress HIV-1 replication in treatment-naive patients [3]. Darunavir
(DRV) is a potent and well tolerated protease inhibitor with no observed resistance during
virologic failure when combined with two NRTIs in treatment-naive patients [4]. Raltegravir
(RAL), an integrase inhibitor, is potent and well tolerated for initial therapy in combination
with two NRTIs, but RAL resistance emerges in approximately one-third of patients with
virologic failure [5]. AIDS Clinical Trials Group (ACTG) Study A5262 was designed to




A5262 participants were treatment-naive, HIV-1-infected adults (≥18 years old) with plasma
HIV-1 RNA concentration (viral load) at least 5000 copies/ml. Exclusion criteria included
active hepatitis B, renal failure requiring dialysis and protocol-specified abnormal laboratory
values. Patients with more than one DRV resistance-associated mutation (RAM) (V11I,
V32I, L33F, I47V, I50V, I54L, I54M, T74P, I84V, and L89V), L76V alone, or known
major integrase RAM (N155H, Q148H/R/K, Y143C/R, and G140S) were also excluded.
Ethics review committees at each research site approved the study. Each participant
provided a written informed consent.
Study design and interventions
Study participants received open-label DRV 800 mg (two 400 mg tablets) and ritonavir 100
mg (one capsule) daily plus RAL 400 mg (one tablet) twice daily. The site investigator was
permitted to construct a new regimen if a patient experienced virologic failure or treatment-
limiting adverse effects.
Procedures and assessments
Study participants had screening, preentry, and entry visits (day 0). Subsequent evaluations
occurred at weeks 1, 4, 12, 24, 36, 48, and 52. At entry and weeks 4, 12, 24, 36, and 48, viral
load, hematology, liver function tests, and blood chemistries were analyzed. Viral load was
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also determined at week 1 in all participants and at week 52 in participants with suspected
virologic failure at week 48. CD4+ and CD8+ T-cell counts were determined at entry and
weeks 12, 24, 36, and 48. Fasting lipid levels were measured at entry and weeks 24 and 48.
Adherence was assessed at weeks 1, 4, 12, 24, and 48 by self-report (number of missed
doses over a 4-day recall) [6]. Plasma samples for trough concentrations (Ctrough) of RAL
and DRV were stored at each visit that had an adherence assessment. Participants with
suspected virologic failure were asked to return for a failure confirmation visit within 7–35
days of collecting the initial failure sample. At the failure confirmation visit, adherence was
assessed and samples collected for viral load, protease and integrase genotype, T-cell counts,
and Ctrough.
Viral load was measured centrally using the Abbott RealTime HIV-1 Test on the m2000
system (Abbott RT/m2000 assay) (Abbott Molecular Inc., Des Plaines, Illinois, USA).
Population sequencing of the integrase and protease genes was performed during virologic
failure. Genotypic mutations according to the 2009 International AIDS Society (IAS) USA
[7] plus G140S for integrase were considered. DRV and RAL plasma concentrations were
determined using internally and externally validated mass spectrometry (RAL) and ultra-
performance liquid chromatography (DRV) methods. All interday and intraday variability
was less than 10%; the lower limits of detection for RAL and DRV were 10 and 50 ng/ml,
respectively.
An independent Study Monitoring Committee reviewed study conduct, safety and efficacy
approximately 24 weeks after enrollment of the 40th participant. To assess the impact of
assay variation on viral load determinations, stored plasma samples from the first 10 patients
with low-level viremia (viral load 51–200 copies/ml) during virologic failure were retested
posthoc using the Roche Amplicor HIV-1 Monitor Test, version 1.5 (Roche Diagnostic
Systems, Branchburg, New Jersey, USA).
Outcome measures
The primary endpoint was virologic failure prior to or at week 24. Virologic failure was
defined as confirmed viral load 1000 copies/ml or more at week 12, or an increase of more
than 0.5 log10 copies/ml in viral load from week 4 to 12 (including rebound to >50 copies/
ml from week 4 to 12 for patients with week 4 value ≤50 copies/ml), or confirmed viral load
more than 50 copies/ml at or after week 24. Secondary outcome measures included virologic
failure through week 48, viral load less than 50 or less than 200 copies/ml at weeks 24 and
48, incidence of adverse events that was at least grade 3 (severe) or any grade if it led to
permanent drug discontinuation, changes in fasting lipid concentrations, protease or
integrase inhibitor resistance during virologic failure, adherence to study treatment, Ctrough
of RAL and DRV, and changes in CD4+ T-cell counts (CD4 cell count).
Statistical analysis
For the primary analysis, the cumulative proportion of participants experiencing virologic
failure at or before week 24 and corresponding two-sided 95% confidence interval (CI) were
estimated using the Kaplan–Meier method and Greenwood’s formula [8]. The primary
efficacy analysis used the intent-to-treat (ITT) approach, including all treated patients
regardless of study treatment modification and censoring follow-up if a participant was lost
to follow-up or died without previously meeting the definition of virologic failure. Enrolled
participants who never started the study treatment were excluded. Log-rank test and Cox
proportional hazards regression were used to assess predictors of virologic failure.
Acceptable virologic failure rate was estimated using week 24 virologic failure rates
observed in large phase III trials of current preferred regimens: efavirenz plus two-NRTI
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arm of ACTG A5142 (22%) [3]; efavirenz plus two-NRTI arm of ACTG A5095 (17%) [9];
and tenofovir/emtricitabine (TDF/FTC) plus RAL (10–15%) [10]. It was prespecified that
RAL plus DRV/r would be considered satisfactory if the upper bound of the CI for
cumulative virologic failure at week 24 was less than 35%. With a sample size of 100
evaluable participants, the study was estimated to have 91% probability that the upper bound
of the two-sided 95% CI for the virologic failure rate would be less than 35% if the
underlying true failure rate was 20%. The planned sample size was increased by 10% to 111
participants to account for loss to follow-up.
Proportions of participants with viral load less than 200 and less than 50 copies/ml at weeks
24 and 48 were estimated using ITT (missing/off study without virologic failure ignored)
and modified ITT (missing/off treatment considered failure) approaches.
Adherence was classified as perfect (zero reported missed doses) or imperfect (any missed
doses of DRV/r or RAL, failure to answer the 4-day recall question, or missed the study
visit). Pharmacokinetic analyses included geometric mean of trough concentrations
[Ctrough(avg)] obtained within a defined window (within 9–15 and 20–28 h after the last dose
for RAL and DRV, respectively). Only Ctrough up to and including the time of virologic
failure confirmation visit was included for participants with virologic failure. Ctrough below
the assay detection limits was replaced with half of the corresponding lower limit of
quantification. Sensitivity analysis examined Ctrough(avg) using all available Ctrough values.
Adverse events were graded according to the severity scale of the Division of AIDS,
National Institutes of Health [11]. Safety analyses used as-treated approach, including all
patients who initiated study treatment and censoring follow-up at treatment discontinuation.
Baseline viral load level and CD4 cell count were calculated as the geometric and arithmetic
means, respectively, of preentry and entry evaluations. Changes in continuous measures
from baseline were assessed by Wilcoxon signed rank test. Comparisons between
participants with and without virologic failure used Wilcoxon rank sum test for continuous
measures, Fisher’s exact test for binary measures and Cochran–Armitage test for ordered
categorical measures.
All P values and CIs presented were two-sided and nominal, unadjusted for interim analysis
and multiple comparisons. Analyses were done using SAS, version 9.2 (SAS Institute, Cary,
North Carolina, USA), StatXact 8 PROCs (Cytel, Cambridge, Massachusetts, USA), and
Splus, version 6 (Insightful, Seattle, Washington, USA).
Results
Study participants
A total of 113 patients were enrolled at 22 sites in the USA. One participant did not initiate
study drugs and was taken off study. Of 112 participants who initiated DRV/r plus RAL
with a median age of 36 years, 88% were men and 44% were white non-Hispanic. Median
CD4 cell count and viral load were 271 cells/μl and 4.87 log10 copies/ml, respectively
(Table 1). Forty-nine (44%) participants had baseline viral load more than 100 000 copies/
ml including six (5%) with levels higher than 750 000 copies/ml. Pretreatment antiretroviral
drug resistance was detected in 21 (19%) participants: nine with (8%) NNRTI, eight (7%)
with NRTI, two (2%) with protease inhibitor, one (1%) with NRTI plus NNRTI, and one
(1%) with NRTI plus NNRTI and protease inhibitor mutations. No participant had a DRV
RAM. Ninety-seven (87%) participants completed 52 weeks follow-up. Fifteen (13%)
participants discontinued participation due to inability to get to clinic (seven), inability of
study staff to reach participant (four), withdrawal of consent (two), unwillingness to adhere
to study requirements (one), and death (one).
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Seventeen participants (16%, 95% CI 10–24) experienced virologic failure by week 24: 11
failed to suppress viral load (one with >1000 copies/ml at week 12; 10 with > 50 copies/ml
at week 24) and six due to viral rebound. Eleven participants experienced virologic failure
(due to viral load rebound to > 50 copies/ml) after week 24. Thus, virologic failure occurred
in 28 participants by week 48 (Table 2); virologic failure rate by week 48 was 26% (95% CI
19–36). Three participants with virologic failure subsequently attained viral load less than
50 copies/ml without changing therapy. In ITT analysis, viral load was less than 50 copies/
ml in 79% (95% CI 70–86) of participants at week 24 and in 71% (95% CI 61–79) at week
48; using modified ITT analysis, viral load was less than 50 copies/ml in 74% (95% CI 66–
82) of participants at week 24 and in 61% (95% CI 52–70) at week 48 (Fig. 1). Viral load
less than 200 copies/ml was achieved in 93% (95% CI 87–97) at week 24 and 86% (95% CI
78–92) at week 48 in ITT analysis and in 88% (95% CI 81–94) and 73% (95% CI 65–81) at
week 24 and 48 in the modified ITT analysis.
Participants with virologic failure had higher baseline viral load (median 5.22 vs. 4.70 log10
copies/ml, P =0.002) and lower baseline CD4 cell count (192 vs. 322 cells/μl, P =0.007)
compared with those who did not experience virologic failure (Table 1). Of the 28
participants with virologic failure, 21 had baseline viral load more than 100 000 copies/ml
and these patients had more rapid time to virologic failure (P <0.001) (Fig. 2). Multivariable
model for time to virologic failure, adjusting for age and sex, demonstrated that virologic
failure was associated with baseline viral load more than 100 000 copies/ml (hazard ratio
=3.76, 95% CI 1.52–9.31, P =0.004) and lower CD4 cell count (hazard ratio =0.77, 95% CI
0.61–0.98 per 100 cells/μl increase, P =0.037). Seventeen (15%) participants were classified
as having imperfect adherence. No association was detected between virologic failure and
adherence, age, sex, intravenous drug use, race/ethnicity, or presence of any mutation at
baseline (all P >0.10).
Seventeen participants with virologic failure (61%) had viral load of 51–200 copies/ml at the
first viral load determination during virologic failure, four (14%) had 201–1000 copies/ml
and seven (25%) had more than 1000 copies/ml. Viral load levels in the first 10 patients with
low-level viremia during virologic failure were similar when determined using the Roche
HIV Monitor v1.5 and Abbott RT/m2000 assays. Baseline CD4 cell count, viral load,
resistance, adherence, and detection of mutations at the time of virologic failure were not
significantly different between participants who failed with viral load higher than 200 vs.
51–200 copies/ml (all P ≥0.40). Participants with virologic failure as a result of failure to
suppress viremia vs. viral rebounders were similar with respect to baseline characteristics
(age, sex, race/ethnicity, intravenous drug use, CD4 cell count, and viral load) and RAL and
DRV trough concentrations/detectability, adherence (all P >0.10).
HIV-1 drug resistance
Integrase resistance testing was successful in 25 of the 28 virologic failures. All five
participants with evidence of integrase RAMs [N155H (one), N155H/N (two), Q148Q/R,
and N155H/N (one), Q148K/Q and N155H/N (one)] had baseline viral load more than 100
000 copies/ml. None of these patients had documented treatment interruption. No new
protease inhibitor RAMs were detected in the 23 participants with successful protease
sequencing following virologic failure.
Pharmacokinetics
Considering the defined trough period, median (quartile 1–quartile 3) Ctrough(avg) was 1218
(789–1809) ng/ml for DRV and 117 (52–250) ng/ml for RAL (Supplementary Table 1,
http://links.lww.com/QAD/A177). DRV and RAL Ctrough(avg) values within the defined
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trough period were not significantly different for patients with and without virologic failure,
perfect vs. imperfect adherence, viral load more than 200 vs. 51–200 copies/ml at the time
of virologic failure, and presence or absence of resistance mutations at virologic failure (all
P >0.10). Similar results were obtained in sensitivity analyses that included all available
DRV and RAL Ctrough except for DRV Ctrough(avg), which was lower in those with virologic
failure (1042 vs. 1649 ng/ml, P =0.017). For RAL, at least one Ctrough below detection limits
(BDLs) occurred in 10/27 (37%) participants with virologic failure compared with seven of
76 (9%) nonvirologic failure participants (P =0.002); for DRV, five of 21 (24%) virologic
failure participants had BDL levels compared to two of 62 (3%) nonvirologic failure
participants (P =0.01) (Table 3). When adjusted for DRV or RAL Ctrough [either continuous
or categorical variable (BDL or not)] as a time-varying covariate with one-study-visit lag (at
the visit immediately before or at all previous visits) in Cox PH models, baseline viral load
more than 100 000 copies/ml remained significantly associated with hazard of virologic
failure (P <0.05). More specifically, when RAL Ctrough was evaluated as a categorical
variable, having RAL Ctrough BDL within the defined trough period at the visit immediately
before was associated with increased hazard of virologic failure (hazard ratio =5.25, 95% CI
1.41–19.58, P =0.014] and the hazard ratio was 5.05 (95% CI 1.64–15.56) (P =0.005) for
baseline viral load; the hazard ratio for having RAL Ctrough BDL at one or more previous
visits was 3.42 (95% CI 1.41–8.26) (P =0.006) and 4.67 (95% CI 1.93–11.25) (P <0.001) for
baseline viral load. Marginally significant association was found between virologic failure
and a DRV Ctrough BDL within the defined trough window at the visit immediately before
(hazard ratio =4.28, 95% CI 0.92–20.04, P =0.065; baseline viral load hazard ratio =3.75,
95% CI 1.13–12.41, P =0.030). The association became significant when all DRV Ctrough
were included (hazard ratio = 3.89, 95% CI 1.32–11.49, P =0.014; baseline viral load hazard
ratio =4.34, 95% CI 1.73–10.86, P =0.002).
Immunological outcomes
The median CD4 cell count increase from baseline was 142 (80–196) cells/μl at week 24
and 200 (114–318) cells/μl at week 48 (all P <0.001) and were similar at week 24 in patients
with baseline viral load less than or equal to or more than 100 000 copies/ml (P >0.1). At
week 48, the median increase was 233 cells/μl in patients with baseline viral load higher
than 100 000 copies/ml vs. 180 cells/μl in those with viral load 100 000 copies/ml or less (P
=0.044).
Safety and tolerability
Twenty-one participants (19%) reported at least one grade 3 (severe) or higher clinical or
laboratory adverse events, five of which were classified as possibly related to study
treatment: dyslipidemia (three), diabetes mellitus (one), and elevated aspartate transaminase/
alanine transaminase (one). No events were considered probably or definitely related to
study treatment. One participant permanently discontinued study treatment due to grade 2
(moderate) maculopapular rash and abdominal pain. Death occurred in one patient at week 9
from cryptosporidiosis.
Median increases in fasting high-density lipoprotein (HDL), low-density lipoprotein, total
cholesterol, and triglycerides from baseline to week 48 were 9, 17, 30, and 23 mg/dl,
respectively (P <0.001, except triglycerides P =0.006). Fasting total cholesterol: HDL ratio
did not change significantly from baseline (0.40 at weeks 24 and 48).
Discussion
In HIV-1-infected treatment-naive participants enrolled in A5262, an RTI-free, two-drug
regimen comprising DRV/r plus RAL met the protocol definition of acceptable virologic
Taiwo et al. Page 6










efficacy (at week 24), but only 71 and 61% of participants had viral load less than 50 copies/
ml (86 and 73% <200 copies/ml) at week 48 in ITT and modified ITT analyses, respectively.
Baseline viral load more than 100 000 copies/ml was associated with an increased risk of
virologic failure. Baseline CD4 cell count per 100-cell increase was associated with reduced
risk of virologic failure. In multivariable models fitted with DRV or RAL Ctrough BDL,
baseline viral load more than 100 000 copies/ml remained strongly associated with increased
risk of virologic failure. Having RAL Ctrough BDL at the visit immediately before or at one
or more previous visits was also associated with an increased hazard of failure.
Potential explanations for our findings were explored. Self-reported adherence (4-day recall)
was not significantly different between those with and without virologic failure, or between
those with baseline viral load less than or equal to or more than 100 000 copies/ml.
However, having one or more DRV and RAL plasma concentrations below detection limits
was significantly more common in those with virologic failure, possibly related to
unreported suboptimal adherence. Other investigators have demonstrated discordance
between self-reported adherence and objectively measured adherence [12]. Adverse effects
of therapy are unlikely to have been the major determinant of adherence or virologic
efficacy as RAL and DRV were well tolerated. An alternative hypothesis is that
asymmetrical dosing of DRV/r (once daily) and RAL (twice daily) predisposed to
suboptimal adherence and virologic failure, but such association has not emerged as a
concern with RAL twice daily plus TDF/FTC, a similarly asymmetrically dosed regimen
[13]. It was suggested recently that RAL–DRV interactions may lower plasma
concentrations of DRV [14], but DRV Ctrough observed in this study (Supplementary Table
1, http://links.lww.com/QAD/A177) are within the range reported in an intensive
pharmacokinetic study of DRV 800/100 mg daily [15]. Finally, because over half of the
patients who experienced virologic failure had low-level viremia (51–200 copies/ml) at the
time of failure, we considered virologic failure artifacts due to assay variability [16]. This
possibility was excluded because viral load determinations during low-level viremia were
similar with the Abbott m2000 and the Roche Amplicor Ultrasensitive Assays in the first 10
participants with low-level virologic failure.
An association between efficacy and baseline viral load has been demonstrated with other
antiretroviral regimens. In some but not all studies of two NRTIs plus a third preferred
agent, smaller proportions of patients with baseline viral load more than 100 000 copies/ml
achieved HIV RNA less than 50 copies/ml at 48 weeks [5,13,17–21], but these differences
tend to be small, are in part related to tolerability and associated with low CD4 cell count
[16], and may not be synonymous with subsequent virologic failure [22]. In our RTI-sparing
study in which we specifically examined virologic failure, as opposed to a combined
endpoint, the differences in virologic outcomes between the high and low viral load strata
were striking and the results were consistent or even more evident in multivariable analyses
that included baseline CD4 cell count or assessments of drug concentrations. A pilot study
evaluating twice-daily atazanavir (ATV) plus RAL was prematurely terminated at week 24
due in part to adverse events and frequent RAL resistance in those with virologic failure
[23]. A larger randomized study, however, found no significant difference in viral load less
than 40 copies/ml at week 48 in patients treated with RAL plus lopinavir/ritonavir (LPV/r)
compared with TDF/FTC plus LPV/r [24]. The mean baseline viral load in the latter study
was 4.25 log10 copies/ml, which is lower than the 4.9 log10 copies/ml in the twice-daily
RAL plus ATV study and 4.83 log10 copies/ml in our study. Our study is also the first to
report virologic outcomes by baseline viral load less than or equal to or more than 100 000
copies/ml separately from nonvirologic treatment discontinuations, further limiting cross-
study comparisons. The mechanisms underlying the poorer virologic outcomes in some
patients with high baseline viral load, as observed in this study, are uncertain. One
possibility is that high baseline viral load may be associated with more extensive reservoir
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of infected cells and prolonged viral decay time to levels below 50 copies/ml. However,
only one of the 28 virologic failures in the current study had viral dynamics that may be
explained solely by this specific hypothesis. Another possibility is that high baseline viral
load may predispose to greater diversity of HIV-1 quasispecies and an increased opportunity
to select drug-resistant mutants. Q148R minority variants were detected at very low levels
(median 0.46%) in 86% of treatment-naive patients in one study [25]. The effect of
pretherapy RAL-resistant minority variants on virologic outcome in treatment-experienced
patients has not been clearly demonstrated [25,26] and to our knowledge has not yet been
reported in treatment-naive patients.
Baseline viral load more than 100 000 copies/ml appears to increase the risk of RAL
resistance in patients receiving DRV/r plus RAL. All the patients with evidence of RAL
resistance mutations at virologic failure (20% of those genotyped) had baseline viral load
more than 100 000 copies/ml. None of these patients had documented treatment interruption,
and no significant difference in RAL Ctrough was observed between those with or without
RAL resistance. Viral load at the time of integrase genotyping in the five participants ranged
from 62 to 685 copies/ml. Notably, a participant who achieved HIV RNA less than 50
copies/ml at week 12 and had no subsequent documentation of viral load level more than
100 copies/ml experienced virologic failure at week 48 with detection of Q148K/Q and
N155H/N. Thus, like NNRTI and NRTI resistance mutations [27], RAL resistance
mutations may be present during low-level viremia [28], an important observation as recent
guidelines state that viral load more than 200 copies/ml can be considered the threshold for
virologic failure in clinical practice [1]. Protease inhibitor resistance was not detected in any
participant experiencing virologic failure, consistent with evidence that boosted protease
inhibitor resistance seldom develops early in virologic failure [29].
Interpretation of this study should take into account its single-arm design as a randomized
trial could have reduced the potential impact of patient characteristics and other variables.
Also, patients were not screened for pretreatment RAL resistance, but primary mutations
that confer resistance to RAL are uncommon in RAL-naive patients [30]. Despite these
limitations, the results of A5262 raise important issues that should be examined carefully in
future clinical trials evaluating DRV/r plus RAL and perhaps in all RTI-sparing two-drug
regimen trials. We urge caution in patients with baseline viral load more than 100 000
copies/ml and emphasize a need to further elucidate the implications of low-level viremia in
patients receiving the regimen.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Appendix
A5262 study team members: Sarah W. Read, Jennifer Janik, Debra S. Meres, Michael M.
Lederman, Lori Mong-Kryspin, Karl E. Shaw, Louis G. Zimmerman, Randi Leavitt
(Merck), Guy De La Rosa (Tibotec), Amy Jennings.
ACTG site investigators: Karen Coleman and Meredith Rathert [Northwestern University
(Site 2701) CTU Grant AI069471]; Edward Seefried and Leticia Muttera [University of
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California San Diego (Site 701) CTU Grant number AI 69432]; Michael F. Para and Heather
Harber [The Ohio State University (Site 2301) CTU Grant AI069474]; Robert Kalayjian and
Ann Marie Anderson [MetroHealth Medical Center (Site 2503) CTU Grant AI-069501];
Kerry Upton and Jenna White [Alabama Therapeutics CRS (Site 5801) CTU Grant U01
AI069452]; Pablo Tebas and Aleshia Thomas [University of Pennsylvania (Site 6201) CTU
Grant U01-AI-69467–05, CFAR Grant P30-AI-045008–12]; Annie Luetkemeyer and Jay
Dwyer [UCSF AIDS CRS (Site 801) CTU Grant 5UO1 AI069502]; Mariea Snell and James
Conner [Washington University in St. Louis (Site 2101) CTU Grant AI 069495]; Nathan M.
Thielman and Jacquelin Granholm [Duke University Medical Center CRS (Site 1601) CTU
Grant 5U01 AI069484]; Carl J Fichtenbaum and Eva Moore [University of Cincinnati (Site
2401) CTU Grant 1U01AI069513]; David Currin and Megan Avots [UNC AIDS Clinical
Trials Unit UNC AIDS CRS (Site 3201) CTU Grant 5-U01 AI069423, CTSA Grant UL
1RR 025747, CFAR Grant AI50410]; Roberto C. Arduino and Maria Laura Martinez
[Houston AIDS Research (HART) (Site 31473) CTU Grant 1U01AI069503]; Mary Albrecht
and Amanda Youmans [Beth Israel Deaconess (Partners/Harvard) CRS (Site 103) CTU
Grant U01 AI069472–05]; Debbie Slamowitz and Sandra Valle [Stanford University AIDS
CTU (Site 501) CTU Grant AI069556]; Princy N. Kumar and Joseph Timpone [Georgetown
University (Site 1008) Grant 5U01AI069494]; Christine Hurley and Roberto Corales [AIDS
Care (Site 1108) CTU Grant U01AI069511–02 (as of 2/12/08), CTSI Grant UL1 RR
024160]; Vicki Bailey and Husamettin Erdem [Vanderbilt Therapeutics CRS (Site 3652)
CTU Grant AI-069439, Grant RR-024975]; Sharon Riddler and Sally McNulty [Pittsburgh
CRS (Site 1001) CTU Grant 1 UO1 AI 069494-01]; Barbara Philpotts and Dawn Antosh
[Case CRS (Site 2501) CTU Grant AI69501].
A5262 is registered with ClinicalTrials.gov (NCT00830804).
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Proportion of participants with HIV-1 RNA level less than 50 and less than 200 copies/ml.
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Kaplan–Meier plots of time to virologic failure (VF) using intent-to-treat approach.
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Table 1




PWith VF Without VF
Age (in years)
 N 112 28 84 0.835*
 Mean (SD) 37 (11) 37 (13) 37 (11)
 Median (Q1–Q3) 36 (27–45) 35 (26–44) 36 (28–45)
 18–29 33 (29%) 9 (32%) 24 (29%) 0.760***
 30–39 38 (34%) 7 (25%) 31 (37%)
 40–49 25 (22%) 7 (25%) 18 (21%)
 50–59 12 (11%) 4 (14%) 8 (10%)
 ≥60 4 (4%) 1 (4%) 3 (4%)
Sex
 Male 98 (88%) 25 (89%) 73 (87%) 1.000**
 Female 14 (13%) 3 (11%) 11 (13%)
Race/ethnicity
 White non-Hispanic 49 (44%) 10 (36%) 39 (46%) 0.618**
 Black non-Hispanic 45 (40%) 14 (50%) 31 (37%)
 Hispanic (regardless of race) 16 (14%) 4 (14%) 12 (14%)
 Asian, Pacific Islander 2 (2%) 0 (0%) 2 (2%)
IV drug history
 Never 102 (91%) 26 (93%) 76 (90%) 0.194**
 Currently 1 (1%) 1 (4%) 0 (0%)
 Previously 9 (8%) 1 (4%) 8 (10%)
Baseline CD4 (cells/μl)
 Mean (SD) 284 (199) 199 (167) 312 (202) 0.007*
 Median (Q1–Q3) 271 (107–419) 192 (51–310) 322 (147–442)
 <200 40 (36%) 15 (54%) 25 (30%) 0.018***
 200 to <350 32 (29%) 8 (29%) 24 (29%)
 350 to <500 26 (23%) 3 (11%) 23 (27%)
 ≥500 14 (13%) 2 (7%) 12 (14%)
Baseline HIV-1 RNA (log10 copies/ml)
 Mean (SD) 4.83 (0.60) 5.14 (0.61) 4.73 (0.57) 0.002*
 Median (Q1–Q3) 4.87 (4.33–5.31) 5.22 (4.85–5.60) 4.70 (4.31–5.16)
Baseline HIV-1 RNA (copies/ml)
 ≤5000 3 (3%) 1 (4%) 2 (2%) 0.006***
 5001 to ≤10 000 5 (4%) 1 (4%) 4 (5%)
 10 001 to ≤100 000 55 (49%) 5 (18%) 50 (60%)
 100 001 to ≤750 000 43 (38%) 18 (64%) 25 (30%)
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Characteristic Total
VF status
PWith VF Without VF
 >750 000 6 (5%) 3 (11%) 3 (4%)
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Table 3
Trough concentration (categorical) by virologic failure status.a
Drug
VF status
Total PbWith VF Without VF
RAL (within true trough time)
 All above detection 17 (63%) 69 (91%) 86 (83%) 0.002
 With ≥1 concentration BDL 10 (37%) 7 (9%) 17 (17%)
 Missing 1 8 9
RAL (all available)
 All above detection 15 (54%) 70 (83%) 85 (76%) 0.004
 With ≥1 concentration BDL 13 (46%) 14 (17%) 27 (24%)
DRV (within true trough time)
 All above detection 16 (76%) 60 (97%) 76 (92%) 0.010
 With ≥1 concentration BDL 5 (24%) 2 (3%) 7 (8%)
 Missing 7 22 29
DRV (all available)
 All above detection 19 (68%) 77 (92%) 96 (86%) 0.004
 With ≥1 concentration BDL 9 (32%) 7 (8%) 16 (14%)




For VF patients, only those concentrations on or before VF confirmation were considered.
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